Indications of axitinib/axitinib

Axitinib/Axitinib (Axitinib) is an important targeted drug mainly used to treat advanced renal cell carcinoma. This cancer originates in the kidneys and may spread to other organs when the disease reaches an advanced stage, forming metastatic kidney cancer.

Axitinib is a tyrosine kinase inhibitor ( TKI), and its mechanism of action is by interfering with intracellular signaling pathways. Specifically, axitinib can effectively block the transmission of growth signals by tyrosine kinases to cancer cells, thereby inhibiting the proliferation and survival of tumor cells. This process not only leads to the death of cancer cells but also slows tumor growth. In addition, axitinib has anti-angiogenic properties, and tumor growth requires sufficient oxygen and nutrients, which are usually provided by the formation of new blood vessels. By inhibiting the formation of new blood vessels, axitinib reduces the supply of oxygen and nutrients to tumors, thereby creating favorable conditions for tumors to shrink or stop growing.

In terms of clinical application, axitinib can be used alone or in combination with other therapies. When used in combination with immunotherapy, the effectiveness of the treatment can often be significantly improved. For example, axitinib, when used in combination with avelumab, has been recommended as a first-line treatment for patients with advanced renal cell carcinoma. In addition, treatment with pembrolizumab is also suitable for first-line treatment. These combination therapies are designed to maximize the therapeutic effect through synergy to improve patient survival and quality of life.

Axitinib is also available as monotherapy and is particularly suitable for patients with second-line advanced renal cancer who have failed to respond to other systemic therapies. Its flexible use allows doctors to develop personalized treatment plans based on the patient's specific conditions, providing effective treatment options for patients with renal cell carcinoma at different stages.

Reference materials:https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/axitinib